ClinicalTrials.gg
CompletedNCT00830076Updated May 15, 2017Results posted

A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)

A Phase 1 interventional study of sitagliptin phosphate and metformin hydrochloride in Type 2 Diabetes Mellitus, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-05-15.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 — 3 open to participants now, 5 under way, none of them phase 3. sitagliptin · Diabetes Mellitus, Type 2.

Enrollment
171st of 197
18 · median 102
Started
2008
with 22 others
Phase 1
23 of 198
none open now
Registered
60th of 198
by date
Lead sponsor
70 of 198
Merck Sharp & Dohme LLC

Among the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, this one is the 171st largest by enrollment of the 197 interventional ones that give a count, is one of 23 that started in 2008, is one of 23 in phase 1, and was the 60th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 198 studies testing sitagliptin in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About sitagliptin

sitagliptin: first FDA approval 2006 (JANUVIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies testing sitagliptin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will assess the effects of sitagliptin and metformin alone and after co-administration on incretin hormone concentrations in patients with Type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female subjects must have a negative pregnancy test
  • Subject has type 2 diabetes and is not currently receiving treatment with an oral AHA agent, has not received such treatment for 3 months prior to study, and/or has not received more than 4 total weeks treatment with an oral AHA agent for 12 to 18 months prior to the study
  • Subject is a nonsmoker or has not smoked and/or used nicotine for at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Subject has a history of stroke, seizures, or major neurological disorders
  • Female subject is breastfeeding
  • Subject cannot refrain from use of any prescription or non-prescription drugs beginning 2 weeks prior to first dose of study drug
  • Subject consumes more than 3 alcoholic beverages per day
  • Subject consumes more than 6 caffeinated beverages per day
  • Subject has had major surgery, or has donated or lost 1 unit of blood within 4 weeks of screening
  • Subject has a history of cancer, except certain skin or cervical cancer or other cancers treated more than 10 years prior to screening
  • Subject has a history of multiple and/or severe allergies or intolerance to drugs or food
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    Sitagliptin + placebo metformin

    Drug: sitagliptin phosphate · Drug: Comparator: placebo metformin

  • Experimental
    Metformin + placebo sitagliptin

    Drug: metformin hydrochloride · Drug: Comparator: placebo sitagliptin

  • Experimental
    Sitagliptin + metformin

    Co-administration of sitagliptin and metformin

    Drug: sitagliptin phosphate · Drug: metformin hydrochloride

  • Placebo comparator
    Placebo sitagliptin + placebo metformin

    Co-administration of placebo to sitagliptin and placebo to metformin

    Drug: Comparator: placebo sitagliptin · Drug: Comparator: placebo metformin

Interventions

  • Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.

    Also known as: Januvia

  • Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.

    Also known as: Glucophage

  • DrugComparator: placebo sitagliptin

    Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.

  • DrugComparator: placebo metformin

    Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.

06

What researchers measure

Primary outcomes

  1. Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations

    Meal was given 2 hours postdose. Blood samples for determination of active GLP-1 concentration were collected (4 hours postmeal) on Day 2 in each treatment period.

    Time frame: 6 hours postdose (4 hours postmeal) on Day 2

Secondary outcomes

  1. β-cell Sensitivity

    β-cell sensitivity was defined as the incremental post-prandial 4-hour area under the curve (AUC) for insulin secretion rate (ISR) normalized by the incremental post-prandial 4-hour plasma glucose AUC.

    Time frame: 6 hour post-dose (4 hour postmeal) on Day 2

  2. Incremental Post-prandial 4-hour Weighted Mean Plasma Glucose Concentrations

    Meal was given 2 hours postdose. Blood samples for determination of glucose concentration were collected (4 hours postmeal) on Day 2 in each treatment period.

    Time frame: 6 hours postdose (4 hours postmeal) on Day 2

07

Results

Posted Nov 3, 2011

Participant flow

Sitagliptin + Placebo Metformin
Participant flow — Sitagliptin + Placebo Metformin
MilestoneAll Participants
Started18
Completed18
Not completed0
7-day Washout
Participant flow — 7-day Washout
MilestoneAll Participants
Started18
Completed18
Not completed0
Metformin + Placebo Sitagliptin
Participant flow — Metformin + Placebo Sitagliptin
MilestoneAll Participants
Started18
Completed18
Not completed0
7-day Washout
Participant flow — 7-day Washout
MilestoneAll Participants
Started18
Completed18
Not completed0
Sitagliptin + Metformin
Participant flow — Sitagliptin + Metformin
MilestoneAll Participants
Started18
Completed18
Not completed0
7-day Washout
Participant flow — 7-day Washout
MilestoneAll Participants
Started18
Completed18
Not completed0
Placebo Sitagliptin + Placebo Metformin
Participant flow — Placebo Sitagliptin + Placebo Metformin
MilestoneAll Participants
Started18
Completed18
Not completed0

Outcome measures

PrimaryIncremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations

Meal was given 2 hours postdose. Blood samples for determination of active GLP-1 concentration were collected (4 hours postmeal) on Day 2 in each treatment period.

Time frame:
6 hours postdose (4 hours postmeal) on Day 2
Reported as:
Least squares mean · picomolar
Incremental Post-prandial 4-hour Weighted Mean Active Glucagon-like Peptide-1 (GLP-1) Plasma Concentrations
picomolarAll Participants
Sitagliptin + placebo metformin6.00 (4.53 to 7.94)
Metformin + placebo sitagliptin4.09 (3.09 to 5.42)
Sitagliptin + metformin7.22 (5.45 to 9.55)
Placebo sitagliptin + placebo metformin1.55 (1.17 to 2.05)
Secondaryβ-cell Sensitivity

β-cell sensitivity was defined as the incremental post-prandial 4-hour area under the curve (AUC) for insulin secretion rate (ISR) normalized by the incremental post-prandial 4-hour plasma glucose AUC.

Time frame:
6 hour post-dose (4 hour postmeal) on Day 2
Reported as:
Least squares mean · (ng/min)/(mg/dL)*10^ -3
β-cell Sensitivity
(ng/min)/(mg/dL)*10^ -3All Participants
Sitagliptin + placebo metformin, n=1719.50 (11.89 to 32.00)
Metformin + placebo sitagliptin, n=1725.71 (15.67 to 42.18)
Sitagliptin + metformin, n=1826.39 (16.18 to 43.05)
Placebo sitagliptin + placebo metformin, n=1815.44 (9.46 to 25.19)
SecondaryIncremental Post-prandial 4-hour Weighted Mean Plasma Glucose Concentrations

Meal was given 2 hours postdose. Blood samples for determination of glucose concentration were collected (4 hours postmeal) on Day 2 in each treatment period.

Time frame:
6 hours postdose (4 hours postmeal) on Day 2
Reported as:
Least squares mean · mg/dL
Incremental Post-prandial 4-hour Weighted Mean Plasma Glucose Concentrations
mg/dLAll Participants
Sitagliptin + placebo metformin42.30 (30.51 to 54.08)
Metformin + placebo sitagliptin29.33 (17.55 to 41.12)
Sitagliptin + metformin20.02 (8.24 to 31.81)
Placebo sitagliptin + placebo metformin51.02 (39.24 to 62.81)

Adverse events

Collected over 43 days (four 2-day treatment periods, a 7-day washout interval between each treatment period, and approximately 14 days following the last dose of study treatment). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sitagliptin + Placebo Metformin—0/18 (0%)4/18 (22.2%)
Metformin + Placebo Sitagliptin—0/18 (0%)3/18 (16.7%)
Sitagliptin + Metformin—0/18 (0%)3/18 (16.7%)
Placebo Sitagliptin + Placebo Metformin—0/18 (0%)4/18 (22.2%)
Most frequent other events
Showing 10 of 15
Most frequent other events
EventSitagliptin + Placebo MetforminMetformin + Placebo SitagliptinSitagliptin + MetforminPlacebo Sitagliptin + Placebo Metformin
HeadacheNervous system disorders0/181/181/182/18
Iron Deficiency anaemiaBlood and lymphatic system disorders1/180/180/180/18
Conjunctival haemorrhageEye disorders1/180/180/180/18
Vision blurredEye disorders0/180/180/181/18
DiarrhoeaGastrointestinal disorders0/180/181/180/18
DyspepsiaGastrointestinal disorders1/181/180/181/18
NauseaGastrointestinal disorders0/180/181/180/18
VomitingGastrointestinal disorders0/180/180/181/18
FatigueGeneral disorders0/180/180/181/18
Vessel puncture site painGeneral disorders0/180/180/181/18

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)All Participants
<=18 years0
Between 18 and 65 years17
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female5
Male13
Region of Enrollment
Region of Enrollment(participants)All Participants
United States18
08

Study locations

No study locations are listed for this record.

09

References and documents

Individual participant data

Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2008 to primary completion in Apr 2009, 4 months.

Results were first posted in Nov 2011, 2 years 6 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 4 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2009
First posted
Jan 27, 2009
StartActual
Dec 2, 2008
Primary completionActual
Apr 30, 2009
CompletionActual
May 14, 2009
Results first posted
Nov 3, 2011
Last update
May 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00830076
Responsible party
Sponsor
First posted
Jan 27, 2009
Start date
Dec 2, 2008
Primary completion
Apr 30, 2009
Completion
May 14, 2009
Results posted
Nov 3, 2011
Last update
May 15, 2017

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sitagliptin · Metformin

Start the discussion